Literature DB >> 27052331

Adrenoceptor modulators and cancer progression.

Kazuyoshi Hirota1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27052331     DOI： 10.1007/s00540-016-2171-8

Source DB:  PubMed          Journal:  J Anesth        ISSN： 0913-8668            Impact factor:   2.078


× No keyword cloud information.
  31 in total

1.  Beta blocker use and colorectal cancer risk: population-based case-control study.

Authors:  Lina Jansen; Janina Below; Jenny Chang-Claude; Hermann Brenner; Michael Hoffmeister
Journal:  Cancer       Date:  2012-05-14       Impact factor: 6.860

2.  Novel naftopidil-related derivatives and their biological effects as alpha1-adrenoceptors antagonists and antiproliferative agents.

Authors:  Junjun Huang; Fei He; Minyi Huang; Xiawen Liu; Yan Xiong; Yajian Huang; Liu Zhu; Ya Yang; Xingjie Xu; Mu Yuan
Journal:  Eur J Med Chem       Date:  2015-04-07       Impact factor: 6.514

Review 3.  Molecular pathways: beta-adrenergic signaling in cancer.

Authors:  Steven W Cole; Anil K Sood
Journal:  Clin Cancer Res       Date:  2011-12-20       Impact factor: 12.531

4.  On statistical relationship between ADRA2A expression and the risk of breast cancer relapse.

Authors:  M Yu Shkurnikov; V V Galatenko; A E Lebedev; V E Podol'skii; E A Tonevitskii; D V Mal'tseva
Journal:  Bull Exp Biol Med       Date:  2014-08-12       Impact factor: 0.804

5.  Naftopidil induces apoptosis in malignant mesothelioma cell lines independently of α1-adrenoceptor blocking.

Authors:  Eriko Masachika; Takeshi Kanno; Takashi Nakano; Akinobu Gotoh; Tomoyuki Nishizaki
Journal:  Anticancer Res       Date:  2013-03       Impact factor: 2.480

6.  Reduction of prostate cancer incidence by naftopidil, an α1 -adrenoceptor antagonist and transforming growth factor-β signaling inhibitor.

Authors:  Daisuke Yamada; Hiroaki Nishimatsu; Shintaro Kumano; Yoshikazu Hirano; Motofumi Suzuki; Tetsuya Fujimura; Hiroshi Fukuhara; Yutaka Enomoto; Haruki Kume; Yukio Homma
Journal:  Int J Urol       Date:  2013-04-21       Impact factor: 3.369

7.  Further data on beta-blockers and cancer risk: observational study and meta-analysis of randomized clinical trials.

Authors:  Matteo Monami; Luca Filippi; Andrea Ungar; Federica Sgrilli; Alessandro Antenore; Ilaria Dicembrini; Paola Bagnoli; Niccolò Marchionni; Carlo Maria Rotella; Edoardo Mannucci
Journal:  Curr Med Res Opin       Date:  2013-02-18       Impact factor: 2.580

8.  Effect of β-blockers and other antihypertensive drugs on the risk of melanoma recurrence and death.

Authors:  Vincenzo De Giorgi; Sara Gandini; Marta Grazzini; Silvia Benemei; Niccolò Marchionni; Pierangelo Geppetti
Journal:  Mayo Clin Proc       Date:  2013-11       Impact factor: 7.616

9.  Beta-blocker usage after malignant melanoma diagnosis and survival: a population-based nested case-control study.

Authors:  C McCourt; H G Coleman; L J Murray; M M Cantwell; O Dolan; D G Powe; C R Cardwell
Journal:  Br J Dermatol       Date:  2014-04       Impact factor: 9.302

10.  Targeting of beta adrenergic receptors results in therapeutic efficacy against models of hemangioendothelioma and angiosarcoma.

Authors:  Jessica M Stiles; Clarissa Amaya; Steven Rains; Dolores Diaz; Robert Pham; James Battiste; Jaime F Modiano; Victor Kokta; Laura E Boucheron; Dianne C Mitchell; Brad A Bryan
Journal:  PLoS One       Date:  2013-03-28       Impact factor: 3.240
View more
  1 in total

Review 1.  The Role of β-Blockers in Melanoma.

Authors:  Vincenzo De Giorgi; Pierangelo Geppetti; Chiara Lupi; Silvia Benemei
Journal:  J Neuroimmune Pharmacol       Date:  2019-09-03       Impact factor: 4.147
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.